TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03159585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAEST16001
Description: After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
Study: NCT02731378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietins (EPO)
Description: A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietins (EPO)
Description: A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggressive iron dextran supplementation
Description: Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
Study: NCT02942277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS01
Description: AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS01
Description: AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.
Study: NCT02731378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietins (EPO)
Description: Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained iron dextran supplementation
Description: Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
Study: NCT02820077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray (Endoscopic treatment with hemostatic powder)
Description: Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
Study: NCT00804453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartridge blood set
Description: Once a week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard blood line
Description: Once a week
Study: NCT00610168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM
Description: Single booster dose of vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM
Description: Single booster dose of vaccine
Study: NCT02557724

Intervention type: PROCEDURE
Intervention: blood samples
Description: liver transplant patients will have (5) 3cc blood samples drawn at specific time points.

Intervention type: PROCEDURE
Intervention: blood samples
Description: liver resection patients will have (3) 3cc. blood samples drawn at specific time points
Study: NCT04632277

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Participants will receive a tab water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water with low Mg
Description: Participants will receive Low Mg bottle water (50mg/l)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water with high Mg
Description: Participants will receive High Mg bottle water (100mg/l)
Study: NCT06010797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Showing Pre-treatment photographs of the patient
Description: Extra-oral and intra-oral dental photographs of patients were taken before starting Orthodontic treatment. Experimental group were shown their photographs while control group were not shown their photographs.
Study: NCT03021811

Intervention type: DEVICE
Group type: OTHER
Intervention: KLOX LumiHeal BioPhotonic System
Description: Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
Study: NCT01587885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg
Description: Capsules, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg
Description: Capsules, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 mg
Description: Tablets, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Description: Tablets, orally
Study: NCT02246738

Intervention type: OTHER
Intervention: Blood Collection

Intervention type: OTHER
Intervention: Blood Collection

Intervention type: OTHER
Intervention: Blood Collection

Intervention type: OTHER
Intervention: Blood Collection
Study: NCT02942277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS01
Description: AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS01
Description: AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.
Study: NCT02246738

Intervention type: OTHER
Intervention: Blood Collection

Intervention type: OTHER
Intervention: Blood Collection

Intervention type: OTHER
Intervention: Blood Collection

Intervention type: OTHER
Intervention: Blood Collection

Intervention type: OTHER
Intervention: Blood Collection
Study: NCT02930057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celestone
Description: all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency treatment
Description: all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pulsed radiofrequency treatment
Description: all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).

Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
Study: NCT02043288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-6004
Description: Study group (3 week/cycle):~NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15
Study: NCT02043288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15
Study: NCT03907696

Intervention type: OTHER
Group type: OTHER
Intervention: Anti-stigma interventions curriculum
Description: educational curriculum aimed at reducing stigma
Study: NCT02575417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Game
Description: The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Game
Description: The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Game
Description: The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
Study: NCT02174224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Case management based on needs-assessment. Resource connection and mentoring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Medical Care
Description: This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
Study: NCT02584283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual hypothermic oxygenated perfusion
Description: Dual hypothermic oxygenated perfusion using the Liver Assist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liver Assist®
Description: The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion fluid
Description: The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
Study: NCT02661230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COGNIPLUS
Description: Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.
Study: NCT00232557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLC-Asthma
Description: Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TLC-health education
Description: A telephone-linked communication system (TLC) to provide general health education.
Study: NCT02571140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: subcutaneous standard injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral PTH (1-34)
Description: Different optimization of API
Study: NCT00580957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blocked
Description: Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intact
Description: Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
Study: NCT01783743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TT Training Program and TT Screening Card
Description: The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
Study: NCT01607593

Intervention type: DRUG
Intervention: sertraline (Zoloft)
Description: Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
Study: NCT03273959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
Study: NCT01676493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine
Study: NCT03572673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexima 3S
Description: Flexima 3S (2-piece appliance) with drainable pouch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New 2-piece ostomy appliance
Description: New 2-piece ostomy appliance with drainable pouch
Study: NCT02842047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop, Breathe & Think™
Description: online daily meditations delivered using smart phone or other computer based application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stop, Breathe & Think™
Description: online daily meditations delivered using smart phone or other computer based application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: End of Life Planning Videos
Description: Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver wellness videos
Description: Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
Study: NCT01368510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Cognitive Behavioral Therapy (CBT)
Description: Nondrug psychotherapy administered daily 5 days/week for 4 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Cognitive Behavioral Therapy (CBT)
Description: Nondrug psychotherapy administered daily 5 days/week for 4 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Minimal contact waitlist weekly for 4 weeks
Study: NCT00619788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4.0-5.0mm AngioSculpt Scoring Balloon Catheter
Description: The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
Study: NCT03561896

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT
Description: Image-Guided Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS
Description: stereotactic radiation therapy
Study: NCT04102293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NSK Endo motor Endomate
Description: Rotary instrumenation used in pulp therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NSK Endo motor Endomate
Description: Rotary instrumenation used in pulp therapy
Study: NCT01899898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified Modified Atkins Diet
Description: Modified Atkins diet with the following modifications:~1. Pictorial representation of various food items and exchange lists will be provided.~2. Instead of weights, we will provide standardized measures~3. We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures~4. We will formulate recipes and diets based on locally available and culturally acceptable foods.~5. We will develop a parent instruction manual.~6. We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.~7. We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiepileptic drugs alone
Description: The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
Study: NCT02499939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Education and home exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Education and home exercises
Study: NCT04591626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT02499939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Therapy
Description: Ultrasound is a therapeutic modality that is used by physical therapists to help reduce local tissue pain and inflammation. Ultrasound is applied using a round-headed wand or probe that is placed in direct contact with the patient's skin. Ultrasound gel is used on all surfaces of the ultrasound head to reduce friction and assist in the transmission of the ultrasonic waves. For the purposes of treatment for CIPN, the ultrasound will be applied for 5 minutes to each limb (right toes, left toes, right fingers, left fingers) at frequency of 3.0 megahertz (MHz) and an intensity of 0.7-0.8 watts per cm2.~(For CIPN, the ultrasound will be administered at a lower intensity in order to avoid a heating effect on the tissues.)
Study: NCT02559427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-week immediate SPA treatment
Description: a comprehensive program soon after randomization including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 3-week late SPA treatment
Description: a comprehensive program after 4.5 months, including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
Study: NCT03043703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirSense 10 AutoSet for Her
Description: Positive airway pressure
Study: NCT00330252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intravenously on day 1 of every week for eight weeks (or 16 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
Study: NCT04709289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid, photodynamic therapy
Description: Aminolevulinic acid, photodynamic therapy
Study: NCT00709228

Intervention type: DRUG
Intervention: PegIntron
Description: 1.5 ug/kg/week

Intervention type: DRUG
Intervention: Rebetol
Description: 800-1200 mg/day
Study: NCT02754063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PbtO2 probes
Description: PbtO2/ICP/CPP-directed therapy according to international recommendations
Study: NCT05111470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm throws with his dominant arm
Description: Seated patient with different sensors on his naked torso. Patients will throw a ball with their dominant arm. The trajectories will be recorded by Vicon MX-40
Study: NCT02754063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No PbtO2 probes
Description: ICP/CPP-directed therapy according to international recommendations
Study: NCT01499303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Phase II Trial to evaluate the efficacy of 200mg fostamatinib
Study: NCT04909398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic pupillometry sessions
Description: The evaluation protocol will include the following steps:~* Installation of the subject, adaptation of the chin rest for the best comfort of the participant~* Calibration of the oculometer consisting of ocular fixation of 9 fixation points distributed on the stimulation screen~* Final validation of the eligibility of the subject in the study according to the success or not of the calibration.
Study: NCT01037556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104
Description: Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.